Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of "Buy" from Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned a consensus recommendation of "Buy" from the seventeen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $33.71.

A number of research firms have recently commented on DNLI. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective on the stock. Morgan Stanley began coverage on Denali Therapeutics in a research note on Friday, March 7th. They issued an "overweight" rating and a $33.00 price objective on the stock. Wedbush dropped their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright dropped their price objective on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price objective on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th.

Denali Therapeutics Price Performance

DNLI stock traded up $0.38 on Thursday, reaching $14.29. The company's stock had a trading volume of 1,008,378 shares, compared to its average volume of 1,096,490. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33. The company has a market capitalization of $2.08 billion, a P/E ratio of -5.18 and a beta of 1.49. The firm has a fifty day moving average of $14.05 and a two-hundred day moving average of $19.42.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the company earned ($0.68) earnings per share. As a group, equities analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DNLI. Caitong International Asset Management Co. Ltd raised its position in Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after buying an additional 1,551 shares during the period. Sterling Capital Management LLC raised its position in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Denali Therapeutics during the first quarter valued at $41,000. GF Fund Management CO. LTD. acquired a new position in Denali Therapeutics during the fourth quarter valued at $62,000. Finally, Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics during the fourth quarter valued at $65,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.